Abstract
In CUP, therapy should be tailored on an individual basis according to the clinico-pathological subset of distinct prognosis to which the patient belongs. The management of patients who are confirmed to have favourable subsets or treatable types of CUP after the stepwise diagnostic approach should follow specific guidelines that are based on site-specific therapy or treatment guidelines of metastatic cancer with a known primary tumour. Further, accurate prognostic predictors are potentially of value in clinical decision-making, allowing optimal treatment to be used in those most likely to gain the greatest benefit, whilst avoiding the unnecessary toxicity of futile anticancer treatment in those unlikely to benefit [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fizazi K, Greco FA, Pavlidis N, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi64–8.
Pentheroudakis G, Lazaridis G, Pavilidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAX) a systematic review of published evidence. Breast Cancer Res Treat. 2010;119:1–11.
Pentheroudakis G, Pavilidis N. Serous papillary peritoneal carcinoma; unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hamatol. 2010;75:27–42.
Varadhachary GR, Raber MN, Matamorous A, et al. Carcinoma of unknown primary with colon cancer profile: changing paradigm and emerging definitions. Lancet Oncol. 2008;9:596–9.
Palma DA, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012;12:305.
Llazaridis G, Pentheroudakis G, Fountrzillas G, et al. Liver metastasis from carcinoma of unknown primary (CUP); a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008;34:693–700.
Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679–83.
Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35:570–3.
Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized phase III Sarah Cannon Research Consortium Trial. Cancer J. 2010;16:70–5.
Culine S, Lortholary A, Voigt JJ, et al. Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479–3482.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Eswar, C. (2017). An Overview of the Management of Cancer of Unknown Primary. In: Seshadri, N., Eswar, C. (eds) PET/CT in Cancer of Unknown Primary. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-56424-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-56424-1_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56423-4
Online ISBN: 978-3-319-56424-1
eBook Packages: MedicineMedicine (R0)